ReShape Lifesciences Files 8-K for Operations Update
Ticker: HIND · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
TL;DR
ReShape Lifesciences dropped an 8-K on April 1st covering financials and ops.
AI Summary
On April 1, 2024, ReShape Lifesciences Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Obalon Therapeutics Inc., is based in San Clemente, California, and operates in the surgical and medical instruments sector.
Why It Matters
This filing provides investors with crucial updates on ReShape Lifesciences' financial condition and operational performance, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial and operational updates, not indicating any immediate or significant new risks.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- Obalon Therapeutics Inc. (company) — Former company name
- April 1, 2024 (date) — Date of earliest event reported
- San Clemente, California (location) — Company address
- 3841 (sic_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on ReShape Lifesciences Inc.'s results of operations and financial condition, as well as to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 1, 2024.
What was ReShape Lifesciences Inc. formerly known as?
ReShape Lifesciences Inc. was formerly known as Obalon Therapeutics Inc.
Where is ReShape Lifesciences Inc. headquartered?
ReShape Lifesciences Inc.'s principal executive offices are located at 18 Technology Dr, Suite 110, Irvine, California, 92618.
What is the Standard Industrial Classification code for ReShape Lifesciences Inc.?
The Standard Industrial Classification code for ReShape Lifesciences Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-04-04 11:12:02
Key Financial Figures
- $0.001 — nge on which Registered Common stock, $0.001 par value per share RSLS The Nasdaq
Filing Documents
- rsls-20240401x8k.htm (8-K) — 34KB
- rsls-20240401xex99d1.htm (EX-99.1) — 195KB
- rsls-20240401xex99d1001.jpg (GRAPHIC) — 4KB
- 0001558370-24-004700.txt ( ) — 364KB
- rsls-20240401.xsd (EX-101.SCH) — 3KB
- rsls-20240401_lab.xml (EX-101.LAB) — 15KB
- rsls-20240401_pre.xml (EX-101.PRE) — 10KB
- rsls-20240401x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On April 1, 2024, ReShape Lifesciences Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto is being "furnished" in accordance with General Instruction B.2 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 1, 2024 104 Cover Page Interactive Data File (embedded with inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Tom Stankovich Tom Stankovich Chief Financial Officer Dated: April 4, 2024